Purpose of review The aim of this study was to assess the seizure manifestations and risk of epilepsy in encephalitis associated with antibodies against neuronal cell-surface (autoimmune encephalitis) or myelin-associated antigens, and to review several chronic epileptic disorders, including Rasmussen's encephalitis, feverinduced refractory epileptic syndromes (FIRES) and new-onset refractory status epilepticus (NORSE).
INTRODUCTION
Epilepsy is a chronic neurological disease defined by the occurrence of at least one unprovoked seizure and the enduring predisposition to seizure recurrence [1] . The hypothesis that inflammation plays a role in epileptogenesis has long been suggested [2 & ]. This hypothesis has been reinforced by the identification of several autoimmune encephalitis that associates with seizures and occurs with antibodies against neuronal cell-surface or myelin-related proteins. The study of these disorders has provided new insights into the relationship between neuroinflammation, autoimmunity and seizure generation, giving rise to the concept of 'autoimmune epilepsy'. In the context of autoimmune encephalitis, the development of seizures and status epilepticus usually represents an acute, symptomatic manifestation of the brain inflammatory process, but little is known about the risk of developing chronic epilepsy. Chronic epilepsy might potentially result from an ongoing inflammatory process that persists after the acute phase of encephalitis, or from irreversible changes that alter neuronal networks and persist after the inflammatory process resolves. Therefore, although neuroinflammation may trigger symptomatic seizures, this does not necessarily imply that the subsequent development of chronic seizures is inflammation-dependent. Likewise, herpes simplex encephalitis may cause acute
Inflammation, autoimmunity and epileptogenesis
A number of clinical observations have suggested that inflammatory pathways are involved in epileptogenesis [3, 4] , including the anticonvulsant effect of steroids in some paediatric forms of epilepsy [5] , the role of fever in triggering febrile-related epilepsies [6, 7] , the higher frequency of epilepsy in systemic autoimmune diseases (e.g. systemic lupus erythematosus and others) [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , the increased prevalence of serum autoantibodies in chronic epilepsy (e.g. antinuclear and antiphospholipid antibodies) [20, 21] and the involvement of immunerelated genes in some types of epilepsy and febrileseizure susceptibility [22] .
On the contrary, seizures and status epilepticus can cause neuroinflammation through several mechanisms including among others, activation of the interleukin (IL)-1b system by microglia, resulting in a cascade of inflammatory processes involving neurons, endothelial cells and astrocytes, and likely responsible for blood-brain barrier breakdown and neuronal dysfunction, with alteration of the balance between excitatory and inhibitory neurotransmission [23,24 & ], and the involvement of the high-mobility-group box 1 (HMGB1), a danger signal that results in activation of downstream inflammatory pathways through interaction with its receptor (Toll-like receptor 4) [2 & ].
The immune system, and in particular its adaptive arm, may contribute to epileptogenesis [ ,33], and were found at a higher frequency (15-37%) when the seizures were refractory to antiepileptic treatment [34, 35] . However, with the exception of glutamic acid decarboxylase 65(GAD65) antibodies, the significance of antibodies in chronic epilepsy is unclear because they are usually identified only in serum and may disappear over time despite seizure recurrence [31] . Careful consideration should be given to the interpretation of antibodies against proteins interacting with voltage-gated potassium channels (VGKC complex). These antibodies are in fact directed against two neuronal cell-surface proteins, leucine-rich glioma inactivated-1 (LGI1) and contactin-associated protein-2 receptor (CASPR2) [36, 37] In anti-NMDAR encephalitis, seizures are more often the first clinical manifestation in men than in women, and in children younger than 12 years [67, 68] . Age-related clinical differences have also been reported in anti-GABA A R encephalitis in which children are more likely to develop generalized seizures than adults who predominantly develop focal seizures [47,52 & ]. Although there is a substantial clinical overlap among different autoimmune encephalitis, some symptoms, electroencephalogram (EEG) or MRI findings may suggest the autoantigen. For instance, the EEG pattern named extreme delta brush has been found in children and adults with anti-NMDAR encephalitis and is highly characteristic of this disorder, although it is only detectable in a subgroup of patients [54, 69] . Extensive multifocal cortical-subcortical T2/FLAIR MRI abnormalities occur in approximately 80% of patients with anti-GABA A R encephalitis, but rarely occur in other autoimmune encephalitis [47, 52 ]. Facio-brachial dystonic seizures (FBDS) typically precede the development of anti-LGI1 encephalitis, which often occurs in association with other seizures. FBDS are brief (typically 1-2 s) unilateral or bilateral motor seizures, affecting the limbs and face, with a frequency that can be over 100 In more than 70% of patients with autoimmune encephalitis, the associated seizures are successfully treated with immunotherapy and antiepileptics, and most do not require chronic antiepileptic medication [29, 49, 73, 74] . A study on autoimmune encephalitis associated with antibodies against neuronal cell-surface or intracellular antigens reported good seizure response to rituximab in cases refractory to corticosteroids, intravenous immunoglobulins and plasma exchange [74] . Overall, the risk of developing chronic epilepsy after autoimmune encephalitis appears low (10-15%) and varies according to the target autoantigen [38
For example, in two cohorts of patients with anti-AMPAR and anti-GABA B R encephalitis, none of the survivors had persistent seizures [45, 56] . Patients with anti-NMDAR encephalitis may have residual cognitive and behavioural deficits but rarely develop chronic epilepsy [53] .
In patients with anti-LGI1 encephalitis, a high seizure frequency associates with the development of mesial temporal lobe sclerosis (MTS) [75] . In these patients, the degree of hippocampal atrophy correlates with memory deficits and delay in implementing immunotherapy [49,50 In patients with autoimmune encephalitis and seizures who do not respond to immunotherapy, epilepsy surgery has been suggested as an alternative treatment; however, this appears to be less effective than in patients with epilepsy unrelated to autoimmune encephalitis [79] [80] [81] .
Autoimmune demyelinating syndromes and myelin oligodendrocyte glycoprotein antibodies
Seizures occur in 11-43% of patients with acute disseminated encephalomyelitis (ADEM), including generalized (40%) and focal (< 20%) seizures, and in 0-14% of patients with clinically isolated syndromes CIS, mostly generalized seizures) [82] [83] [84] [85] [86] [87] [88] [89] 90 & ,91]. There is limited information about the risk of chronic epilepsy in these patients. In a recent study, three of eight children with ADEM had seizures at disease onset, and one developed epilepsy; however, the interval between ADEM and onset of epilepsy was 15 years, making it unclear whether there was a link between the diseases [88] .
Antibodies against myelin oligodendrocyte glycoprotein (MOG) have been identified in about 40% of patients with ADEM and 0-38% of CIS, as well as in a variety of other demyelinating disorders that do not manifest with seizures [82 -89,90 & ]. In patients with ADEM, the presence of MOG antibodies seems to predict a monophasic course and associates with younger age, larger bilateral brain MRI abnormalities and better outcome [84] . Future studies should assess the long-term risk of epilepsy in ADEM and CIS, and investigate whether MOG antibodies segregate with a higher or lower risk of epilepsy.
Epilepsy associated with GAD65 antibodies
High titres of GAD65 antibodies may be found in patients with seizures in the context of limbic encephalitis [92, 93] , and in patients with chronic epileptic syndromes without clinical or MRI evidence of active central nervous system (CNS) inflammation [92] [93] [94] [95] . In particular, GAD65 antibodies have been reported in 2-3% of adults and 6-7% of children with chronic epilepsy [94, 96] . An important consideration in assessing the relationship of GAD65 antibodies with epilepsy and other neurological syndromes is that these antibodies also occur in 1% of healthy people and 80% of patients with type 1 diabetes mellitus [97, 98] . Compared with healthy people or patients with diabetes, patients with neurological symptoms have substantially higher titres of serum antibodies (100-1000 times higher), and the antibodies are detectable in cerebrospinal fluid (CSF) [92, 93, 99] .
As GAD65 is an intracellular antigen and is not accessible to circulating antibodies, the pathogenic role of GAD65 antibodies is controversial. It is thought that other mechanisms, such as T-cell mediated processes or additional antibodies to yet unknown antigens, might be involved [100 & ]. Patients with epilepsy and GAD65 antibodies show poor response to immunotherapy. In a retrospective study of 13 patients, only one patient remained seizure-free after discontinuation of immunotherapy, and similar results were obtained in other studies [101, 102] .
Epilepsy in Rasmussen's encephalitis
Rasmussen's encephalitis is a rare chronic epileptic syndrome that predominantly affects previously healthy children but in rare instances may also occur in adults [103] [104] [105] [106] . Patients develop frequent, unilateral motor seizures that evolve to intractable epilepsia partialis continua, hemiplegia and cognitive decline, accompanied by progressive unilateral hemispheric atrophy [107] [108] [109] . Younger patients are more likely to develop more severe disease and a higher degree of hemispheric atrophy [107] . The cause of this disorder is unclear, but cytotoxic T-cell mechanisms are thought to be involved [110] [111] [112] [113] . Although a number of autoantibodies have been reported in patients with Rasmussen's encephalitis [114] [115] [116] [117] , their pathogenic significance and clinical utility are uncertain. For example, antibodies against the GluA3 (or GluR3) subunit of AMPAR have not only been reported in 4-25% of patients with Rasmussen's encephalitis but also in 40-60% of patients with focal or generalized epilepsy unrelated to Rasmussen's encephalitis [114] [115] [116] [117] . Antibodies against the GluN2 subunit of the NMDAR, as well as other neuronal proteins, have been inconsistently identified in some patients with Rasmussen's encephalitis [115, [118] [119] [120] [121] . Importantly, the AMPAR and NMDAR antibodies identified in Rasmussen's encephalitis are different from those associated with anti-AMPAR or NMDAR encephalitis: the target subunits are different (GluA1/GluA2 in anti-AMPAR encephalitis and GluN1 in anti-NMDAR encephalitis), the epitopes in Rasmussen's encephalitis are linear instead of conformational and are located in the intracellular and not extracellular domain of the receptors [53, 120, 122, 123] . Moreover, the appearance of these antibodies in patients with Rasmussen's encephalitis is often delayed from the time of seizure onset [124] , and the findings are not reproducible across different laboratories.
Seizure control in Rasmussen's encephalitis is challenging: antiepileptics are inefficient and the response to immunotherapies is often poor or transient [125] [126] [127] . Natalizumab or rituximab have shown some efficacy, but these treatments have not been tested in controlled trials [128] [129] [130] . Functional hemispherectomy is the only therapeutic option to achieve long-term seizure control; it is efficacious in 70-80% of the patients but at the expense of irreversible loss of neurological functions [131] .
Fever-induced refractory epileptic syndrome and new-onset refractory status epilepticus
FIRES is a devastating epileptic syndrome occurring in previously healthy children around the age of 5-12 years [132] . It is characterized by frequent seizures developing in the context of a nonspecific febrile episode that rapidly evolve to status epilepticus and chronic pharmacoresistant epilepsy associated with severe neurodevelopmental delay [132] [133] [134] . The brain MRI is initially normal, but as the disease progresses, mesio-temporal T2/FLAIR hyperintensities become apparent and almost all patients eventually develop cerebral atrophy and MTS [135] . Due to the refractoriness of status epilepticus, patients frequently need pharmacologically induced coma. Anaesthetics are often inefficient and their prolonged use seems to negatively influence cognitive outcome [136] .
The cause of FIRES is unclear [133, 134, 137, 138] . Although inflammation is thought to play a pathogenic role, the evidence is inconclusive. CSF oligoclonal bands and testing for neuronal autoantibodies are usually negative [133, 134, 139] . A few patients have been reported with antibodies against VGKC complex (unknown antigen), GAD65 or GluA3, but these findings were not confirmed in other studies [133, 139] . Immunotherapy is usually ineffective [133, 134, 136] .
NORSE is a descriptive term used to indicate the onset of refractory status epilepticus in adults or children without a previous history of epilepsy [140] . A multicentre study on patients with NORSE for whom the underlying cause could not be determined during the first 48 h of presentation, found that in 40%, the cause was autoimmune, and in the other 60%, the cause remained unknown [34] . In recent reports, the use of immunotherapy improved the outcome of 42-75% of patients with NORSE but approximately 30% developed chronic epilepsy [141, 142] .
CONCLUSION
In patients with autoimmune encephalitis and seizures associated with antibodies against neuronal cell-surface proteins, the response to immunotherapy is substantially better than in those with CNS disorders that appear to be related to T-cell mediated mechanisms, such as Rasmussen's encephalitis or GAD65 antibody-associated epilepsy. The long-term risk to develop epilepsy is low in neuronal cell-surface antibody-associated encephalitis (<15%) and moderate in NORSE (30%). Future studies should assess whether early recognition of these disorders and prompt immunotherapy decrease the risk of chronic epilepsy, and whether T-cell targeted immunotherapies may have a role in some disorders. A better understanding of the inflammatory processes underlying chronic epileptogenesis is critical for developing novel treatments.
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